Details of the Drug

General Information of Drug (ID: DM1S2FZ)

Drug Name
Cemdisiran
Indication
Disease Entry ICD 11 Status REF
Haemolytic uraemic syndrome 3A21.2 Phase 2 [1]
Paroxysmal nocturnal haemoglobinuria 3A21.0 Phase 2 [2]
Drug Type
Small interfering RNA
Sequence
>Subunit 1
AAGCAAGAUAUUUUUAUAAUAN
>Subunit 2
UAUUAUAAAAAUAUCUUGCUUUUTT
Cross-matching ID
PubChem CID
126480325
UNII
S66Z65E10T
DrugBank ID
DB16121
TTD ID
D3J9XC

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
C5 messenger RNA (C5 mRNA) TT2LJRF CO5_HUMAN Inhibitor [3]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 ClinicalTrials.gov (NCT03303313) A Study of an Investigational Drug, Cemdisiran (ALN-CC5), in Patients With Atypical Hemolytic Uremic Syndrome. U.S. National Institutes of Health.
2 ClinicalTrials.gov (NCT02352493) A Phase 1/2 Study of an Investigational Drug, ALN-CC5, in Healthy Adult Volunteers and Patients With PNH. U.S. National Institutes of Health.
3 Clinical pipeline report, company report or official report of Alnylam Pharmaceuticals.